Table 4.

P‐Values of chronic toxicity evaluation for inhaled thymol based on the 16 Category‐1 PAPs with t test

#	Treatment group pairs		Group‐3 vs Group‐1	Group‐3 vs Group‐2	Group‐4 vs Group‐1	Group‐4 vs Group‐2
	Treatment dose pairs (weekly mouse thymol dose relative to human dose due to use of epinephrine HFA)		117 vs 0	117 vs 0	858 vs 0	858 vs 0
	A. Lung	# Examined	32	32	32	32
1	• Congestion	P‐value	.91	.93	.50	.62
2	• Hemorrhage; acute	P‐value	.89	.72	.79	.57
3	• Hyperplasia; bronchioloalveolar; focal	P‐value	.21	.14	.84	.84
	B. Lymph node, bronchi	# Examined	23	25	30	26
4	• Focus; mast cells; sinus	P‐value	.64	.45	.87	.69
5	• Hemorrhage; acute	P‐value	.97	.95	.76	.63
6	• Pigment; brown macrophages	P‐value	.21	.59	.28	.70
	C1. Nasal turbinate level I	# Examined	32	32	32	32
7	• Eosinophilic substance; Septum	P‐value	.58	.79	.58	.77
	C2. Nasal turbinate level II	# Examined	32	32	32	32
8	• Dilatation; Bowman's Gland; Duct, or Lateral Wall/Turbinate, or Septum	P‐value	.16	.29	.25	.39
9	• Eosinophilic Substance; Septum	P‐value	.64	.65	.64	.64
10	• Hemorrhage; Acute; Nasolacrimal Duct	P‐value	.37	.50	.50	.66
11	• Hyperplasia; Bowman's Gland; Septum	P‐value	.50	.65	.35	.50
	C3. Nasal turbinate leveL III	# Examined	32	32	32	32
12	• Dilatation; Bowman's Gland; Duct, or Lateral Wall/Turbinate, or Septum	P‐value	.50	.50	.63	.63
13	• Eosinophilic Substance; Septum	P‐value	.37	.56	.31	.50
	C4. Nasal turbinate level IV	# Examined	32	32	32	32
14	• Dilatation; Bowman's Gland; Septum	P‐value	.98	.84	.92	.50
15	• Hyperplasia; Bowman's Gland; Septum	P‐value	.98	.84	.79	.27
	D. Trachea	# Examined	32	32	32	31
16	• Dilation; Gland with Cell Debris	P‐value	.95	.80	.83	.48